Blood Cancer OncTalk 2023 / Series number 7

Article and Video CATEGORIES

Cancer Journey

ABOUT

Aaron Goodman, MD, is a hematologist who specializes in treating a variety of blood cancers, including acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and multiple myeloma. He performs stem cell transplants for cancer treatment, including autologous (stem cells come from the individual receiving the transplant) and allogeneic (stem cells come from a matched donor) transplants.

Blood Cancer OncTalk 2023 / Series number 7

AlexandraGBeneke

Mon, 03/11/2024 - 15:00

Q&A Session: Leading oncologists come together to discuss emerging treatment options and data regarding blood cancer, including multiple myeloma and lymphoma.

Author

Aaron Goodman MD, Guest Faculty

In this last batch of the Q&A Session of Blood Cancer OncTalk, Drs. Aaron Goodman, Sridevi Rajeeve, Tycel Phillips, Alakrita Taneja, and Marco Ruiz come together to answer questions from the attendees at our Blood Cancer OncTalk 2023 live event.

To watch the complete playlist click here.

Video Language

English

Please feel free to offer comments and raise questions in our
discussion forums.

Join The conversation

Next Previous link

Previous Post Next Post

Article

Las biopsias líquidas están revolucionando la forma en que combatimos el cáncer, ofreciendo un futuro donde la detección y el tratamiento son más rápidos, precisos y menos invasivos.

Videoteca de Cáncer de Pulmón en Español 2025

Video

Como parte de la Videoteca de Cáncer de Pulmón en Español 2025, oncólogos expertos discuten las opciones de tratamiento y la información más emergente en cáncer de pulmón. El Dr. Raez aborda la terapia para cánceres de pulmón EGFR y ALK, además de analizar otros tres temas de actualidad. La Dra. Viola y la Dra. Riaño también contribuyen a esta videoteca, cada una presentando tres temas relevantes sobre el cáncer de pulmón.

Unlocking Precision in Lung Cancer: Understanding and Overcoming Resistance to EGFR and ALK Inhibitors

Article

The journey to conquer lung cancer is paved with scientific discovery, and the identification of the EGFR and ALK genes as crucial players marks a significant milestone. Unraveling how mutations in these seemingly small segments of our DNA can unleash the destructive force of cancer has opened up exciting new therapeutic avenues. This exploration delves into the cutting-edge world of EGFR and ALK-targeted therapies, highlighting the progress made and the ongoing quest for even more effective and personalized strategies to combat this formidable disease.